



### UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/613,006	07/10/2000	Mark A. Schena	M-9216 US	9156
24251 7590 12/12/2001			EXAMI	NER
SKJERVEN MORRILL MACPHERSON LLP 25 METRO DRIVE SUITE 700 SAN JOSE, CA 95110		FORMAN, BETTY J		
			ART UNIT	PAPER NUMBER
			1655 DATE MAILED: 12/12/2001	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
Advisory Action	09/613,006	SCHENA, MARK A.		
Advisory Action	Examiner	Art Unit		
	BJ Forman	1655		
The MAILING DATE of this communication appe				
THE REPLY FILED 03 December 2001 FAILS TO PLAC Therefore, further action by the applicant is required to ave final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	) a timely filed amendment whic I (with appeal fee); or (3) a timel	h places the application in		
•	EPLY [check either a) or b)]			
<ul> <li>a)</li></ul>	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailin S FILED WITHIN TWO MONTHS OF T	HE FINAL REJECTION. See MPEP		
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).				
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CF	R 1.191(d)), to avoid dismissai d	eriod set forth in of the appeal.		
2. The proposed amendment(s) will not be entered b				
(a) they raise new issues that would require furth	er consideration and/or search	(see NOTE below);		
(b) they raise the issue of new matter (see Note I	below);			
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or				
(d) they present additional claims without cancel NOTE:	ling a corresponding number of	finally rejected claims.		
3. Applicant's reply has overcome the following reject	tion(s):			
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).				
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attached Continuation of Advisory Action.				
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.				
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims we	nt(s) a)⊡ will not be entered or l would be rejected is provided be	b)⊡ will be entered and an low or appended.		
The status of the claim(s) is (or will be) as follows:				
Claim(s) allowed:				
Claim(s) objected to:				
Claim(s) rejected: <u>1 and 3-26</u> .				
Claim(s) withdrawn from consideration:				
8. ☐ The proposed drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.				
9. Note the attached Information Disclosure Stateme	9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)			
10. Other: PTOL-206 and Interview Summary				





# UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICAN	NT I	ATTORNEY DOCKET NO.
09/1613,000	0 10 12/2000	Shera		M9216-45
1	•		E	XAMINER
Г		٦	7 B FORMAN	
		· ·	ART UNIT	PAPER NUMBER
			1655	10
			DATE MAILED:	

The decision on the petition filed in the above entitled application is as follow	rs:
Delay in Prosecution Held Unavoidable (35 U.S.C. 133),  Petition Granted	
Delayed Payment of Issue Fee Accepted (35 U.S.C. 151),  Petition Granted  Petition Granted 37 CFR (84/6)(2)	
Petition Denied  Petition Dismissed  By direction of the Deputy Assistant Commissioner for Patents	W. Gary Jones
	Supervisory Patent Examiner

Technology Center 1600





## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office


Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

		·	•		
SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICAN	T A	TTORNEY DOCKET NO.	
09/617,006	10 1.1/1000	Schena		M9216-US	
4			EX	AMINER	
<del>-</del>		٦	B Fo	BFORMAN	
		•	ART UNIT	PAPER NUMBER	
			165.5	10	
			DATE MAILED:		


The decision on the petition filed in the above entitled application is as follows:	ws:
Delay in Prosecution Held Unavoidable (35 U.S.C. 133),  Petition Granted	
Delayed Payment of Issue Fee Accepted (35 U.S.C. 151),  Petition Granted  Petition Granted 37 CFR 1.84/6)(2)	
Petition Denied	
By direction of the Deputy Assistant Commissioner for Patents	Wellen-
	W. Gary Jones Supervison/ Potent if securing

Technology on am root!









Art Unit: 1655


#### **Continuation of Advisory Action**

Applicant argues that one of skill in the art would understand that the claimed "synthetic oligonucleotides" refers to oligonucleotides prepared by chemical synthesis and because Lashkari et al. do not teach chemically synthesized oligonucleotides, they do not anticipate the claimed invention. Additionally, Applicant argues that the examiner has misconstrued the term "synthetic oligonucleotide" by citing one of three definitions provided by Academic Press. The arguments are not found persuasive for the reasons stated in the previous action i.e. because "synthetic" as defined by Academic Press Dictionary of Science and Technology (Morris, C. ed. Academic Press, 1992, page 2157) means "any product or item that is the result of human technology rather than something that exists in nature". It is noted that the Academic Press Dictionary provides three definitions one of which is quoted above and is referred by the dictionary as an engineering definition. The first definition provided by the dictionary is referred to as the science definition which recites "relating to, produced by, or involving synthesis." The second definition provided by the dictionary is referred to as the chemistry definition which recites "relating to compounds formed artificially by chemical synthesis." Therefore, given the three similar definitions of "synthetic" provided, the labeled cDNA and the labeled genomic DNA both of which are produced by synthesis; both of which are the result of human technology; both of which do not exist in nature; and both of which are artificially formed are, according to standard scientific definitions and terminology, "synthetic". Therefore, the labeled cDNA and labeled genomic DNA of Lashkari et al. are encompassed by the claimed "synthetic oligonucleotides".

Applicant provides two descriptions of chemically synthesized oligonucleotides wherein the chemically synthesized oligonucleotides are referred to as synthetic oligonucleotides. While the references illustrate that chemically synthesized oligonucleotides are "synthetic oligonucleotides", the references do not define chemically synthesized oligonucleotides as the only form of "synthetic oligonucleotides". Additionally, the references do not teach that "synthetic oligonucleotides" are only chemically synthesized oligonucleotides and they do not teach that labeled cDNA and labeled genomic DNA are not "synthetic oligonucleotides".

Applicant further argues that cDNA and genomic DNA of Lashkari et al. not properly described as oligonucleotides because it was known in the art that oligonucleotides are generally 50 nucleotides or less. This argument is not found persuasive because while Lashkari et al. is silent regarding the length of their probes, they teach their cDNA and genomic DNA are synthesized by primer extension (page 13058, left column first and second full





Art Unit: 1655

paragraphs) which inherently produces fragments of various sizes. Therefore, their synthesized cDNA and genomic DNA probes inherently includes oligonucleotides of 50 nucleotides or less.

Applicant argues that the cDNAs of Brown et al. are distinguishable from the claimed synthetic oligonucleotides for the reasons discussed above regarding the Lashkari et al. reference. The arguments have been considered, but are not found persuasive for the reasons stated above regarding Lashkari et al.

Applicant further argues that Wang et al. and Fodor et al. do not remedy the defects of Brown et al. The argument is not found persuasive for the reasons stated above i.e. the labeled cDNAs of Brown et al. are encompassed by the claimed "synthetic oligonucleotides".

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (703) 306-5878. The examiner can normally be reached on 6:45 TO 4:15.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-8724 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

BJ Forman, Ph.D. Patent Examiner Art Unit: 1655 December 6, 2001 Setomer